Prescribing information




REVOLADE achieved an early platelet response in ITP patients in the RAISE study:1

  • Median platelet count increased from 16,000/µL (IQR 8,000–22,000/µL) to 36,000/µL (IQR 13,000–74,000/µL) after 1 week of REVOLADE treatment
  • In comparison, the median platelet count for the placebo group remained between 17,500/µL (IQR 8,000–29,000/µL) and 23,000/µL (IQR 10,000–40,000/µL)
  • Some patients achieved a response* as early as Day 8
Icon with a calendar  expressing the doubling of platelet counts after 1 week

Line graph showing the increase in media platelet count over 28 weeks

*Response: platelet count higher than 50,000/µL at least once in the absence of rescue therapy.

Abbreviations: IQR, interquartile range; ITP, immune thrombocytopenia.


  1. Cheng G, et al. Lancet. 2011;377:393–402.
  2. Data on file REVDOF001.
HCP19-C002e(1) June 2020.

For more information, refer to the REVOLADE® (eltrombopag olamine) Summary of Product Characteristics:

Legal Category: POM.

Aluminium blisters (PA/Alu/PVC/Alu) in a carton containing 14 or 28 film-coated tablets and multipacks containing 84 (3 packs of 28) film-coated tablets. Marketing Authorisation (MA) number, quantities and NHS price: EU/1/10/612/002 – 25 mg x 28 tablet pack £770, EU/1/10/612/005 – 50 mg x 28 tablet pack £1540, EU/1/10/612/008 – 75 mg x 28 tablet pack £2310



Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]